View : 639 Download: 0
Efficacy of da-9701 (motilitone) in functional dyspepsia compared to pantoprazole: A multicenter, randomized, double-blind, non-inferiority study
- Title
- Efficacy of da-9701 (motilitone) in functional dyspepsia compared to pantoprazole: A multicenter, randomized, double-blind, non-inferiority study
- Authors
- Jung H.-K.; Lee K.J.; Choi M.-G.; Park H.; Lee J.S.; Rhee P.-L.; Kim N.; Park K.S.; Choi S.C.; Lee O.Y.; Huh K.C.; Song G.A.; Hong S.J.; Sohn C.I.; Jung H.-Y.; Lee Y.C.; Rew J.S.; Jee S.R.; Kwon J.G.
- Ewha Authors
- 정혜경
- SCOPUS Author ID
- 정혜경
- Issue Date
- 2016
- Journal Title
- Journal of Neurogastroenterology and Motility
- ISSN
- 2093-0879
- Citation
- Journal of Neurogastroenterology and Motility vol. 22, no. 2, pp. 254 - 263
- Keywords
- DA-9701 (Motilitone); Dyspepsia; Proton pump inhibitor
- Publisher
- Journal of Neurogastroenterology and Motility
- Indexed
- SCIE; SCOPUS; KCI
- Document Type
- Article
- Abstract
- Background/Aims The effect of proton pump inhibitors (PPI) in Asian functional dyspepsia (FD) patients has not been well established as in Western countries. DA-9701, a novel prokinetic agent, stimulates gastric emptying and modulates visceral hypersensitivity in vivo and in human studies. This study was conducted to compare the efficacy of DA-9701 with a conventional PPI in mono or combination therapy in patients with FD. Methods In this double-blind, randomized, non-inferiority trial, 389 patients diagnosed with FD using Rome III criteria were allocated among 3 groups: 30-mg DA-9701 t.i.d (means 3 times a day), 40-mg pantoprazole, and 30-mg DA-9701 t.i.d + 40-mg pantoprazole. The primary efficacy end-point was a global assessment of the patient binary response or response on a 5-Likert scale after 4 weeks. Results The global symptomatic improvement was 60.5% in the DA-9701 group, 65.6% in the pantoprazole group, and 63.5% in the DA- 9701 + pantoprazole group using a 5-Likert scale at week 4 with no significant difference among 3 groups (P = 0.685). Symptom improvement measured by binary outcome was significantly achieved in each of the 3 groups, but not different among groups. Patients in all treatment groups reported significant improvement in the response rate and symptoms according to FD subtypes and dyspepsia-related quality of life (P < 0.001), but there were no significant differences among the 3 groups. Conclusions DA-9701 improves global and individual symptoms and increases dyspepsia-specific quality of life in patients with FD. The efficacy of DA-9701 monotherapy is comparable with pantoprazole and there is no additive effect with combination of DA-9701 and pantoprazole in patients with FD. © 2016 The Korean Society of Neurogastroenterology and Motility.
- DOI
- 10.5056/jnm15178
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML